Search Our Site

Amazon Smile logo

Logo

Your donations allow us to protect the doctor-patient relationship.

On November 1, 2021 the Oklahoma, Alcohol, Tobacco, and Controlled Substances Committee held a hearing. The  purpose was to discuss an interim study that was done about rapid de-prescribing and the horrific effects it has had on patients.  This was requested and organized by Tamera Stewart-P3Alliance Policy Director, Julia Heath-P3Alliance Director of Medical Initiatives, along with their leadership team.

Some of the speakers were Beth Darnall ,PhD from Stanford University, Dr. Vanila Singh, other doctors, a pharmacist, and chronic pain patients.

Beth Darnall, Phd:

Many states have prescribing laws.  Read An Examination of State and Federal Opioid Analgesics and Continuing Education policies which was printed in 2020. We've also included the pdf version of the article. The purpose of the article is "To evaluate the impact of its Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) program, the US Food and Drug Administration (FDA) requested the opioid manufacturers responsible for implementing that program provide information regarding opioid policy changes from 2016 to 2018. FDA also requested a survey of state requirements for pain and opioid prescribing continuing education (CE), the number of prescribers affected by those requirements, the extent to which a REMS-compliant CE program would meet each state‚Äôs requirements, and the number of relevant CE programs available."  

We've included two charts that list prescribing laws state by state

  1. This includes state laws and Continuing Education laws
  2. Laws limiting the prescribing and dispensing of opioids done by the Network For Public Health Law

See our Advocacy Tools to see tips on how to start the process of getting legislation in your state.

The Doctor Patient Forum

Claudia A. Merandi 5 Chedell Avenue / East Providence, RI 02914 / USA 1.401.523.0426

Follow Us: FACEBOOK REDDIT YOU TUBE TIK TOK 2 TWITTER